Varenicline for Smoking Cessation in Patients with Coronary Heart DiseaseClinical & Population Health Research
UMMS AffiliationClinical and Population Health Research Program; Department of Medicine, Division of Cardiovascular Medicine
Medical Subject HeadingsBenzazepines; Quinoxalines; Smoking Cessation; Cardiovascular Diseases
AbstractDespite the decline in cigarette smoking over the past 40 years, self-reported data from the National Health Interview Survey show that 19.8% (43.4 million) of US adults were still smokers in 2007.1 Attempts to quit during the previous year in the general population decreased from 47% in 1993 to 38.8% in 2007, and only 4% to 7% of smokers trying to quit each year will eventually succeed. Cardiovascular diseases are the leading cause of death in Western countries, and cigarette smoking has a clear cause-and-effect relationship with atherosclerotic disease with the risk of myocardial infarction (MI) increasing with the number of cigarettes smoked. Similarly strong evidence indicates that smoking cessation alone can result in a 36% reduction in the crude relative risk of mortality in smokers who quit versus those who do not.5 The risk decreases rapidly: after only 1 year of cessation, quitters have a lower relative risk (RR=0.63) of death from coronary heart disease (CHD) than do nonquitters, which decreases even further (RR=0.38) after 3 years of cessation. Consequently, efforts to find effective treatments to enhance smoking cessation are of great importance.
Rights and PermissionsCitation: Ockene I, Salmoirago-Blotcher E. Varenicline for smoking cessation in patients with coronary heart disease. Circulation. Jan 19 2010;121(2):188-190.
Related ResourcesLink to article in PubMed
Citation InformationIra S. Ockene and Elena Salmoirago Blotcher. "Varenicline for Smoking Cessation in Patients with Coronary Heart Disease" Vol. 121 Iss. 2 (2010) ISSN: 1524-4539
Available at: http://works.bepress.com/elena_salmoiragoblotcher/1/